MX2020003126A - Derivados de iminopirimidina ciclicos como inhibidores de cinasa. - Google Patents
Derivados de iminopirimidina ciclicos como inhibidores de cinasa.Info
- Publication number
- MX2020003126A MX2020003126A MX2020003126A MX2020003126A MX2020003126A MX 2020003126 A MX2020003126 A MX 2020003126A MX 2020003126 A MX2020003126 A MX 2020003126A MX 2020003126 A MX2020003126 A MX 2020003126A MX 2020003126 A MX2020003126 A MX 2020003126A
- Authority
- MX
- Mexico
- Prior art keywords
- cyclic
- derivatives
- iminopyrimidine
- kinase inhibitors
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561142P | 2017-09-20 | 2017-09-20 | |
| PCT/US2018/052047 WO2019060611A1 (en) | 2017-09-20 | 2018-09-20 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003126A true MX2020003126A (es) | 2020-10-01 |
Family
ID=64457074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003126A MX2020003126A (es) | 2017-09-20 | 2018-09-20 | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11254680B2 (enExample) |
| EP (1) | EP3684772B1 (enExample) |
| JP (1) | JP7394768B2 (enExample) |
| KR (1) | KR102796209B1 (enExample) |
| CN (1) | CN111247152B (enExample) |
| AU (1) | AU2018338098B2 (enExample) |
| BR (1) | BR112020005455A2 (enExample) |
| CA (1) | CA3076202A1 (enExample) |
| MX (1) | MX2020003126A (enExample) |
| WO (1) | WO2019060611A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102796209B1 (ko) * | 2017-09-20 | 2025-04-16 | 에이비엠 쎄라퓨틱스 코포레이션 | 키나아제 억제제로서의 시클릭 이미노피리미딘 유도체 |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| ES3018143T3 (en) * | 2019-12-10 | 2025-05-14 | Hoffmann La Roche | New braf inhibitors as paradox breakers |
| WO2021250521A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
| MX2023001312A (es) * | 2020-08-07 | 2023-04-12 | Abm Therapeutics Corp | Inhibidores de quinasa y usos de los mismos. |
| CN114380697A (zh) * | 2021-11-30 | 2022-04-22 | 上海毕得医药科技股份有限公司 | 一种n-甲基乙基胺盐酸盐的制备工艺 |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| CN117209503B (zh) * | 2023-09-13 | 2025-10-17 | 苏州翔实医药发展有限公司 | 一种5,6-二氢咪唑并[1，2-c]喹唑啉及其衍生物合成的方法 |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| WO2025153057A1 (zh) * | 2024-01-17 | 2025-07-24 | 海思科医药集团股份有限公司 | 一种含braf抑制剂的药物组合物及其在医药上的应用 |
| WO2025176185A1 (zh) * | 2024-02-23 | 2025-08-28 | 海思科医药集团股份有限公司 | 一种braf抑制剂的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE411996T1 (de) * | 2002-09-30 | 2008-11-15 | Bayer Healthcare Ag | Kondensierte azolpyrimidinderivate |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| US20100216779A1 (en) | 2007-06-01 | 2010-08-26 | Glaxosmithkline Llc | Imidazopyridine Kinase Inhibitors |
| EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
| EP2348020A1 (en) | 2009-12-23 | 2011-07-27 | Esteve Química, S.A. | Preparation process of erlotinib |
| RU2550038C2 (ru) | 2010-12-02 | 2015-05-10 | Медпакто Инк. | Новое производное пуринилпиридиниламино-2,4-дифторфенилсульфонамида, его фармацевтически приемлемая соль, способ его получения и фармацевтическая композиция, обладающая ингибирующей активностью в отношении raf-киназы, содержащая данное соединение в качестве активного ингредиента |
| US20130023531A1 (en) | 2011-01-27 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| BR112015005562A2 (pt) * | 2012-09-14 | 2017-08-08 | Eternity Bioscience Inc | compostos de aminoisoquinolina, suas composições e uso dos novos compostos como inibidores da proteína quinase. |
| WO2014047648A1 (en) | 2012-09-24 | 2014-03-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9321762B2 (en) | 2013-12-11 | 2016-04-26 | Development Center For Biotechnology | Quinazoline compounds, method for preparing the same and use thereof |
| CN105272970A (zh) | 2014-07-03 | 2016-01-27 | 中国药科大学 | 基于色原酮结构的Raf激酶抑制剂及其制备方法和用途 |
| JP6826526B6 (ja) | 2014-07-16 | 2021-03-31 | ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ | キノキサリン化合物、それを調製する方法およびその使用 |
| KR102796209B1 (ko) * | 2017-09-20 | 2025-04-16 | 에이비엠 쎄라퓨틱스 코포레이션 | 키나아제 억제제로서의 시클릭 이미노피리미딘 유도체 |
-
2018
- 2018-09-20 KR KR1020207010704A patent/KR102796209B1/ko active Active
- 2018-09-20 JP JP2020538750A patent/JP7394768B2/ja active Active
- 2018-09-20 WO PCT/US2018/052047 patent/WO2019060611A1/en not_active Ceased
- 2018-09-20 EP EP18808139.2A patent/EP3684772B1/en active Active
- 2018-09-20 MX MX2020003126A patent/MX2020003126A/es unknown
- 2018-09-20 AU AU2018338098A patent/AU2018338098B2/en active Active
- 2018-09-20 CN CN201880067947.0A patent/CN111247152B/zh active Active
- 2018-09-20 BR BR112020005455-0A patent/BR112020005455A2/pt active Search and Examination
- 2018-09-20 CA CA3076202A patent/CA3076202A1/en active Pending
- 2018-09-20 US US16/648,908 patent/US11254680B2/en active Active
-
2022
- 2022-01-13 US US17/575,292 patent/US11932647B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220251089A1 (en) | 2022-08-11 |
| AU2018338098A1 (en) | 2020-05-07 |
| RU2020113707A3 (enExample) | 2021-12-23 |
| KR20200055034A (ko) | 2020-05-20 |
| EP3684772B1 (en) | 2023-12-06 |
| JP2020534373A (ja) | 2020-11-26 |
| US20200247813A1 (en) | 2020-08-06 |
| EP3684772C0 (en) | 2023-12-06 |
| CA3076202A1 (en) | 2019-03-28 |
| CN111247152B (zh) | 2024-07-16 |
| WO2019060611A1 (en) | 2019-03-28 |
| US11254680B2 (en) | 2022-02-22 |
| BR112020005455A2 (pt) | 2020-09-24 |
| AU2018338098B2 (en) | 2024-02-22 |
| US11932647B2 (en) | 2024-03-19 |
| EP3684772A1 (en) | 2020-07-29 |
| CN111247152A (zh) | 2020-06-05 |
| RU2020113707A (ru) | 2021-10-20 |
| JP7394768B2 (ja) | 2023-12-08 |
| KR102796209B1 (ko) | 2025-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
| ZA202401324B (en) | Tyrosine kinase inhibitors | |
| ZA202405294B (en) | Heterocyclic compounds as immunomodulators | |
| MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
| NZ718190A (en) | Substituted quinazolines for inhibiting kinase activity | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| MY199705A (en) | Heterocyclic compounds as immunomodulators | |
| PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
| MX2018016046A (es) | Quinazolina y compuestos indol para tratar trastornos medicos. | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| EA027213B9 (ru) | Соединения пиразолопиримидина в качестве ингибиторов киназ | |
| MX2024000253A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
| MX362855B (es) | Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp). | |
| AU2018380132A8 (en) | Tubulin inhibitors | |
| MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
| EA201790603A1 (ru) | Ингибиторы гистондеметилазы | |
| MX376090B (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas. | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| MX2020005342A (es) | Compuestos de pirazolopiridinona. | |
| MX2020005344A (es) | Compuestos de pirazolopiridinona. | |
| MX364859B (es) | Derivados de imidazopirazinona. | |
| EA201690376A1 (ru) | Ингибиторы дезоксицитидинкиназы | |
| MX2017014752A (es) | Nuevos etinos de amidoheteroaril aroil hidrazida. | |
| MX2018005515A (es) | Derivados de 1,4-dicarbonil-piperidilo. |